Data / Form D filings / Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc.: Form D filings
Aligos Therapeutics, Inc., a biotechnology company in South San Francisco, CA, filed 3 Form D notices with the SEC between 2020 and 2025. The latest, on February 28, 2025, reports $105 million sold of a $105 million offering to 12 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- One Corporate Dr., 2nd Floor, South San Francisco, CA, 94080
- Phone
- (800) 466-6059
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1799448
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | New notice | $105,003,206 | $105,003,206 | 12 | Feb 11, 2025 | sec.gov | |
| Nov 7, 2023 | New notice | $92,150,000 | $92,150,000 | 11 | Oct 25, 2023 | sec.gov | |
| Jan 16, 2020 | New notice | $125,000,167 | $85,000,001 | $40,000,166 | 38 | Dec 23, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bridget Peter Martell | Director | |
| Julian Peter Symons | Executive Officer | |
| Margarita Peter Chavez | Director | |
| K. Peter Hirth | Director | |
| Heather Peter Preston | Director | |
| Lesley Ann Calhoun | Executive Officer | |
| Lawrence M. Blatt | Executive Officer, Director | |
| James Peter Scopa | Director | |
| Hardean Peter Achneck | Executive Officer | |
| Carole Peter Nuechterlein | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Feb 24, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Aligos Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.